Trials / Completed
CompletedNCT00273871
Study Comparing Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients
A Multi-centre, Randomized, Open-label, Study to Compare Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients on Maintenance Therapy With Mild to Moderate Renal Insufficiency.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 190 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine the effect of conversion from calcineurin inhibitor based therapy to Rapamune based therapy in patients with mild to moderate renal insufficiency.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cyclosporin or tacrolimus |
Timeline
- Start date
- 2002-01-01
- Completion
- 2006-09-01
- First posted
- 2006-01-09
- Last updated
- 2011-03-08
Source: ClinicalTrials.gov record NCT00273871. Inclusion in this directory is not an endorsement.